A Proof of Concept Top Evaluate a Novel Penile Lengthening Protocol
- Conditions
- Penile Elongation
- Registration Number
- NCT04231422
- Lead Sponsor
- Judson Brandeis
- Brief Summary
The objective of this study is to examine and quantify the efficacy and safety of a new treatment protocol using platelet-rich plasma for penile length enhancement.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
- Stretched penile length between 3.5 - 8.0 in
- Age 20-55 years of age
- Desire penile length elongation
- Willing to complete all aspects of combined treatment plan
- Able to measure erect penile length and mid-shaft girth at 1-month intervals
- Judged to be in good health based on medical history, physical exam, and laboratory profile
- Is willing and able to cooperate with the requirement of the study (e.g. completion of all planned study visits)
Exclusion Criteria
- No prior surgical Peyronie's disease treatment
- No chordee with or without hypospadias
- No infiltration by benign or malignant mass
- No active STD
- No infiltration by an infectious agent such as lymphogranuloma venereum
- No uncontrolled psychiatric conditions
- No uncontrolled neurologic conditions
- No other uncontrolled medical conditions such as HTN or DM
- No history of spontaneous priapism
- Is unable to safely use the study devices as determined by the principal investigator
- No thrombosis of the dorsal penile artery or vein
- No known history of coagulation disorder
- No known history of stroke, bleeding, or another significant medical conditional which the investigator deems makes the subject unsuitable for enrollment in the study
- Testosterone level lower than 500
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Stretched penile length baseline to six months Change in length of stretched, flaccid penile length
- Secondary Outcome Measures
Name Time Method SHIM Score baseline to six months Change in erectile function
Safety Measurement baseline to six months Incidence of adverse events and serious adverse events
BDD-YBOCS baseline to six months Change in body dysmorphia scale
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie penile elongation with platelet-rich plasma therapy?
How does platelet-rich plasma compare to standard-of-care treatments for penile length enhancement in terms of efficacy and safety?
Are there specific biomarkers that predict optimal patient response to platelet-rich plasma-based penile lengthening protocols?
What are the potential adverse events associated with platelet-rich plasma application in penile lengthening, and how can they be managed?
What combination therapies or alternative compounds have shown promise in penile elongation research alongside platelet-rich plasma?
Trial Locations
- Locations (1)
BrandeisMD
🇺🇸San Ramon, California, United States
BrandeisMD🇺🇸San Ramon, California, United StatesJudson Brandeis, MDContact510-587-3000Judson@BrandeisMD.comScott LuSub Investigator